55478-23-4

Basic information

• Product Name: Z-DAB(Z)-OH
• Synonyms: Z-ALPHA,GAMMA-DIAMINOBUTYRIC ACID(Z)-OH;Z-DAB(Z)-OH;N-ALPHA,GAMMA-BIS-Z-L-2,4-DIAMINOBUTYRIC ACID;N-ALPHA,GAMMA-D-DICARBOBENZOXY-L-ALPHA,GAMMA-DIAMINOBUTYRIC ACID;Z-L-Dab(Z)-OH;Nα,γ-Bis-Z-L-2,4-diaminobutyric acid99%
• CAS NO: 55478-23-4
• Molecular Formula: C₂₀H₂₂N₂O₆
• Molecular Weight: 386.4
• Mol File: 55478-23-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 646.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.281±0.06 g/cm3(Predicted)
• PKA: 3.88±0.10(Predicted)
• CAS DataBase Reference: Z-DAB(Z)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Z-DAB(Z)-OH(55478-23-4)
• EPA Substance Registry System: Z-DAB(Z)-OH(55478-23-4)

Safety Data

• Hazardous Substances Data: 55478-23-4(Hazardous Substances Data)

Usage

General Description

Z-DAB(Z)-OH is a chemical compound with the molecular formula C13H11NO2. It is an inhibitor of dipeptidyl peptidase IV (DPP-IV), which plays a role in regulating glucose levels in the body. Z-DAB(Z)-OH is used in research to study the role of DPP-IV in diabetes and other metabolic disorders. It has also been investigated for its potential in the treatment of cancer, as well as its antiviral and antimicrobial properties. The compound is soluble in organic solvents such as ethanol and DMSO, and is stable under normal conditions. However, its reactivity and stability in various chemical environments are important factors to consider when handling and using Z-DAB(Z)-OH in laboratory settings.

Upstream product

• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 1482-98-0 (S)-2,4-diaminobutyric acid dihydrochloride 
• 501-53-1 benzyl chloroformate 
• 1482-98-0 L-2,4-diaminobutyric acid monohydrochloride 

Downstream Products

• 118507-50-9 (3S)-3-benzyloxycarbonylamino-2-pyrrolidinone 
• 4127-89-3 N-((S)-2,4-bis-benzyloxycarbonylamino-butyryl)-L-leucine 
• 55478-28-9 N-((S)-2,4-bis-benzyloxycarbonylamino-butyryl)-glycine hydrazide 
• 55478-26-7 N^α,N^γ-Di-Z-L-α,γ-Dab-N^γ-Z-L-α,γ-Dab-NHNH2 
• 1356085-24-9 6-N-benzyloxycarbonyl-2',3'-O-benzylidene-5'-O-[N-(2,4-di(benzyloxycarbonylamino)-L-butyryl)sulfamoyl]adenosine 
• 55478-22-3 N^α,N^γ-Di-Z-L-α,γ-Dab-N^γ-Z-L-α,γ-Dab-OMe 
• 55478-25-6 N-((S)-2,4-bis-benzyloxycarbonylamino-butyryl)-glycine ethyl ester 
• 154491-37-9 ((S)-2,4-Bis-benzyloxycarbonylamino-butyrylamino)-acetic acid methyl ester 
• 4218-64-8 (S)-2,4-bis-benzyloxycarbonylamino-butyric acid amide 
• 4127-88-2 Dibenzyloxycarbonyl-L-α,γ-diamino-butyryl-D-leucin-ethylester 
• 102317-34-0 (S)-3-benzyloxycarbonylamino-2-oxo-pyrrolidine-1-carboxylic acid benzyl ester 
• 4127-88-2 N-((S)-2,4-bis-benzyloxycarbonylamino-butyryl)-L-leucine ethyl ester 

Relevant articles and documents

NOVEL COMPOUNDS AND METHODS OF USE TREATING FRUCTOSE-RELATED DISORDERS OR DISEASES

Disclosed herein are novel compounds that inhibit fructokinase (KHK or ketohexokinase) and the downstream metabolic effects mediated by fructose metabolism. Fructokinase inhibitors specifically block the metabolism of both dietary and endogenous fructose